17.82
price down icon0.28%   -0.05
after-market 시간 외 거래: 17.64 -0.18 -1.01%
loading

Apellis Pharmaceuticals Inc 주식(APLS)의 최신 뉴스

pulisher
Jun 18, 2025

Apellis Pharma general counsel Watson sells $93k in stock By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 16, 2025

Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 12, 2025

How To Trade (APLS) - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech

Jun 12, 2025
pulisher
Jun 11, 2025

Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth By Investing.com - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Apellis Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025
pulisher
Jun 09, 2025

Apellis phase 3 Empaveli data demonstrates sustained proteinuria reduction - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN - Yahoo

Jun 09, 2025
pulisher
Jun 09, 2025

Wealth Enhancement Advisory Services LLC Has $1.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jun 08, 2025
pulisher
Jun 07, 2025

Apellis, Sobi present data from open-label period of Phase 3 VALIANT study - Yahoo Finance

Jun 07, 2025
pulisher
Jun 07, 2025

Apellis Pharmaceuticals (APLS) Reports Promising Phase 3 Study R - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Susta - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals (APLS) Reports Promising Empaveli Data - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report? - Yahoo Finance

Jun 06, 2025
pulisher
Jun 06, 2025

Sobi and Apellis data underscore Aspaveli potential - The Pharma Letter

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals, Inc. and Sobi Announce EMPAVELI®? (Pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals, Sobi Report Empaveli's Sustained Efficacy at 1 Year in Phase 3 Study - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals and Sobi Present Promising Phase 3 VALIANT Study Results for EMPAVELI in Treating Rare Kidney Diseases at European Renal Association Congress - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Breakthrough: EMPAVELI Achieves 68% Disease Reduction in Rare Kidney Conditions as FDA Decision Approaches - Stock Titan

Jun 06, 2025
pulisher
Jun 05, 2025

High Growth Tech Stocks To Watch In The US June 2025 - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Ann - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | APLS Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Reveals New Insights at Goldman Sachs Healthcare Conference: How to Watch Live - Stock Titan

Jun 04, 2025
pulisher
Jun 03, 2025

Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

Wells Fargo & Company Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Up 7.7% Following Analyst Upgrade - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

These 10 Stocks Blew Past Expectations - Insider Monkey

Jun 02, 2025
pulisher
Jun 02, 2025

Apellis Pharmaceuticals (APLS) Receives Price Target Boost from Wells Fargo | APLS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Wells Fargo Adjusts Price Target for Apellis (APLS) to $29 | APLS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Wells Fargo raises Apellis Pharmaceuticals stock price target to $29 By Investing.com - Investing.com Canada

Jun 02, 2025
pulisher
Jun 02, 2025

Wells Fargo Adjusts Price Target on Apellis (APLS) Amid Product Launch Anticipation | APLS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,578 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Apellis Pharmaceuticals Insiders Sell US$3.1m Of Stock, Possibly Signalling Caution - simplywall.st

May 31, 2025
pulisher
May 31, 2025

(APLS) Long Term Investment Analysis - news.stocktradersdaily.com

May 31, 2025
pulisher
May 31, 2025

Equities Analysts Offer Predictions for APLS Q2 Earnings - Defense World

May 31, 2025
pulisher
May 26, 2025

Nuveen Asset Management LLC Has $15.67 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

May 26, 2025
pulisher
May 24, 2025

Citigroup Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World

May 24, 2025
pulisher
May 22, 2025

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts - Benzinga

May 22, 2025
pulisher
May 22, 2025

APLS: Citigroup Lowers Price Target for Apellis Pharmaceuticals | APLS Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Grow - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Growth Outlook | APLS Stock News - GuruFocus

May 22, 2025
pulisher
May 20, 2025

How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com

May 20, 2025
pulisher
May 20, 2025

Apellis Pharmaceuticals Stock: Have Some Patience (NASDAQ:APLS) - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

May 20, 2025
pulisher
May 20, 2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

May 20, 2025
pulisher
May 17, 2025

Mizuho Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $20.00 - Defense World

May 17, 2025
pulisher
May 15, 2025

Northern Trust Corp Has $17.46 Million Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

May 15, 2025
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.23
price up icon 0.63%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):